At the archive date, Zoetis Inc. was expected to release its Q3 2026 10-Q filing on November 2, 2026, before market open. Last quarter: Zoetis Q2 2026 revenue was flat as U.S. companion animal declines offset international growth, while EPS rose slightly due to share repurchases.
EPS Estimate
$1.52
Revenue Estimate
$2.32B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the ZTS page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Total revenue was essentially flat, decreasing $6M, with an operational decline of 2% driven by volume decreases from key franchises and the MFA divestiture, partially offset by other in-line product growth and favorable foreign exchange of 2%.
U.S. companion animal revenue fell 11% due to heightened competitive pressure on Simparica Trio and dermatology, price sensitivity, and generic erosion on Cerenia and Convenia, partially offset by livestock growth from cattle product demand related to the New World screwworm outbreak.
International segment operational revenue grew 5%, led by parasiticides, small animal diagnostics, and mAb pain products (Lenivia and Portela), with additional benefit from favorable FX of $35M (3%) primarily from the Brazilian real and euro.
Revenue
$2.47B
-0.24% YoY
EPS (Diluted)
$1.65
+1.23% YoY
Add ZTS to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.